Table 3.
Ongoing trials of nivolumab in advanced NSCLC.
| Phase | Line of treatment | Control arm | Experimental arm | Clinical trial gov. number |
|---|---|---|---|---|
| I (CHECKMATE 012) | Second line and beyond | – | Nivolumab + ipilimumab, nivolumab + platinum doublet, nivolumab + erlotinib | NCT01454102 |
| III (CHECKMATE 026) | First line | Platinum doublet | Nivolumab | NCT02041533 |
| I | Second line and beyond | – | Nivolumab + EGF816 or INC280 | NCT02323126 |
| III (CHECKMATE 078) | Second line | Docetaxel | Nivolumab | NCT02613507 |
| III (CHECKMATE 227) | First line | Platinum doublet | Nivolumab, nivolumab + ipilimumab, nivolumab + platinum doublet | NCT02477826 |
| II (CHECKMATE 568) | First line | – | Nivolumab + ipilimumab | NCT02659059 |
| I | First line | – | Nivolumab + ceritinib | NCT02393625 |